RxDoctor Payments Data

Stephen Nagy, MD

Ophthalmology · Winston-Salem, NCNPI 1538123161

Payments from drug & device makers

$24,843in general payments, 2019–2025

Across 154 payments — averaging $161.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$20K
  • Alcon$2K
  • AbbVie$891
  • Sight Sciences, Inc.$189
  • Ocular Therapeutix, Inc.$170
  • Harrow Eye, LLC$161
  • plus $975 from 18 others

What the payments were for

  • Speaking & faculty fees$281%
  • Food & beverage$4,75198%
  • Gifts$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,843 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$246,889
Medicare patients
445
Services billed
2,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$65,715
RocklatanNetarsudil Mesylat/Latanoprost76$38,963
LumiganBimatoprost57$25,408
CombiganBrimonidine Tartrate/Timolol35$9,518
VyzultaLatanoprostene Bunod26$9,271
SimbrinzaBrinzolamide/Brimonidine Tart22$9,119
Latanoprost635$8,196
Travoprost44$7,444
Bromfenac Sodium47$5,450
RhopressaNetarsudil Mesylate11$4,158
Cyclosporine13$3,721
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat222$3,674
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,656
Ketorolac Tromethamine103$2,579
Prednisolone Acetate76$2,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$891$100,640163 claims
Bausch & Lomb Americas Inc.Vyzulta$44$9,27126 claims
AlconSimbrinza$2,206$9,11922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Winston-Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →